The Royalty Investor
How Funds Buy, Value and Finance Music Catalogs and Pharmaceutical Royalties: Publishing and Masters, Decay Curves, Rate Setting, Synthetic Royalties, Patent Cliffs, Securitization, Fund Returns and the Career
On 1 April 2023 a fund pays $144.0 million for the publisher's share of about 1,150 songs it did not write and cannot change. The songwriter keeps the writer's share. The fund owns a slice of other people's revenue, paid before most costs, that gets a little smaller every year.
The Royalty Investor is a practitioner's guide to how funds buy, value and finance music catalogs and pharmaceutical royalties, from how a song earns and who sets its rates to decay curves, catalog loans, synthetic royalties, patent cliffs, Medicare negotiation, marks, fund economics and the career. One fictional manager and its fund are followed from January 2023 to September 2026 through three investments, and every figure comes from one model.
Some of what the arithmetic shows: how a decay curve that takes 18 percent a year off a song aged 3 and 1 percent off a song aged 30 turns a 12.0 times multiple into an IRR of 6.0 percent, 7.3 percent if decay is slow and 2.3 percent if it is fast; why one point on the discount rate moves a catalog from $147.8 million to $135.0 million; why a loan at 7.00 percent lowers a projected 6.3 percent return to 5.7 percent while coverage stays at 1.79x and 1.83x against a 1.40x covenant; how royalty tiers of 6.0, 4.0 and 2.0 percent turn projected sales of $520 million into a projected $30.8 million; why a royalty with a base IRR of 14.2 percent has a probability-weighted IRR of 12.5 percent, and would return minus 2.5 percent after a hypothetical safety setback; and how a fund with a gross IRR of 7.3 percent ends at a net IRR of 4.5 percent, a net TVPI of 1.11x and no carried interest.
Current to October 2026, with each real-world fact dated: recorded music and publishing revenue in 2025, the Phonorecords IV streaming rates and the Phonorecords V proceeding, the MLC, music royalty securitizations, the record year for pharmaceutical royalty funding, Medicare price negotiation and the interest rates of 2026. Not investment, legal or tax advice.
The model is not described, it is supplied: a companion workbook rebuilds the case by live formula, and the checklists come as an editable document.
What you will be able to do:
- Explain the size of recorded music and publishing in 2025 and why streaming made catalogs investable
- Take a song's income apart: performance, mechanicals, synchronization, print, the writer's share and the publisher's share
- Read the Copyright Royalty Board's rate decisions and the role of the Music Modernization Act and the MLC
- Build a decay curve by age of songs and value a publishing catalog by multiple of net publisher's share and by discounted cash flow
- Read a masters catalog through net label share and distribution fees, and size a catalog loan with loan-to-value and debt service coverage
- Tell traditional from synthetic royalties, project a medicine's sales to its patent expiry and compute tiered royalties with milestones
- Measure pricing risk under the Inflation Reduction Act and value a royalty across success and failure scenarios
- Explain why marks fall when rates rise, follow a fund's waterfall to its net IRR and TVPI, and plan a career in royalty investing
Seventeen chapters and four appendices: a guide to the workbook, a royalty investor's toolkit of thirteen checklists, thirty-six interview questions with model answers, and a glossary of sixty terms.
Written for analysts, associates and principals at royalty funds and at specialty finance and private credit funds that buy or lend against royalties; for catalog, licensing and business development staff at music and life sciences companies; for bankers and rating analysts on royalty loans and securitizations; and for allocators who look at royalty funds. Part of The Private Markets Career Guides.
How this book was made: written with the help of artificial intelligence tools, under the author's direction; every figure was checked against its source.
Book Info
No download link available yet. You can .
Related Books
Similar recommendations you might enjoy